KR20160048997A

KR20160048997A - 간 x 수용체 (lxr) 조절인자

간 x 수용체 (lxr) 조절인자 Download PDF

Info

Publication number: KR20160048997A
Authority: KR; South Korea
Prior art keywords: alkyl; compound; acceptable salt; optionally substituted; pharmaceutically acceptable
Prior art date: 2013-09-04
Legal status : Withdrawn

Application number

KR1020167008710A

Other languages

English (en)

Korean (ko)

Inventor

라주 모한

Original Assignee

알렉사르 테라퓨틱스 인코퍼레이티드

Priority date

2013-09-04

Filing date

2014-09-04

Publication date

2016-05-04

2014-09-04 Application filed by 알렉사르 테라퓨틱스 인코퍼레이티드 filed Critical 알렉사르 테라퓨틱스 인코퍼레이티드

2016-05-04 Publication of KR20160048997A publication Critical patent/KR20160048997A/ko

Status Withdrawn legal-status Critical Current

Links

102000004311 liver X receptors Human genes 0.000 title claims abstract description 252
108090000865 liver X receptors Proteins 0.000 title claims abstract description 252
150000001875 compounds Chemical class 0.000 claims abstract description 534
238000000034 method Methods 0.000 claims abstract description 144
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
208000035475 disorder Diseases 0.000 claims abstract description 19
201000010099 disease Diseases 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 525
125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 204
229910052739 hydrogen Inorganic materials 0.000 claims description 175
125000001072 heteroaryl group Chemical group 0.000 claims description 174
239000001257 hydrogen Substances 0.000 claims description 174
-1 -C 1 -C 6 alkyl-aryl Chemical group 0.000 claims description 136
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 135
125000003118 aryl group Chemical group 0.000 claims description 134
150000003839 salts Chemical class 0.000 claims description 110
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 107
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 93
229910052736 halogen Inorganic materials 0.000 claims description 73
150000002367 halogens Chemical class 0.000 claims description 72
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 69
150000002431 hydrogen Chemical class 0.000 claims description 66
125000003107 substituted aryl group Chemical group 0.000 claims description 54
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 42
125000004093 cyano group Chemical group *C#N 0.000 claims description 41
230000000694 effects Effects 0.000 claims description 41
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 35
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
229910052799 carbon Inorganic materials 0.000 claims description 24
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
125000001424 substituent group Chemical group 0.000 claims description 21
241000124008 Mammalia Species 0.000 claims description 18
230000009759 skin aging Effects 0.000 claims description 17
201000004624 Dermatitis Diseases 0.000 claims description 16
201000004681 Psoriasis Diseases 0.000 claims description 16
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 13
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 10
230000008569 process Effects 0.000 claims description 9
208000010668 atopic eczema Diseases 0.000 claims description 8
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 7
230000008901 benefit Effects 0.000 claims description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
208000002874 Acne Vulgaris Diseases 0.000 claims description 3
208000024780 Urticaria Diseases 0.000 claims description 3
206010000496 acne Diseases 0.000 claims description 3
125000004438 haloalkoxy group Chemical group 0.000 claims description 3
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 3
230000036573 scar formation Effects 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
125000001475 halogen functional group Chemical group 0.000 claims 3
230000008878 coupling Effects 0.000 claims 1
238000010168 coupling process Methods 0.000 claims 1
238000005859 coupling reaction Methods 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 49
102000037983 regulatory factors Human genes 0.000 abstract description 9
108091008025 regulatory factors Proteins 0.000 abstract description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
230000014509 gene expression Effects 0.000 description 101
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 84
238000006243 chemical reaction Methods 0.000 description 77
239000000243 solution Substances 0.000 description 77
230000002829 reductive effect Effects 0.000 description 74
239000011541 reaction mixture Substances 0.000 description 59
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
150000001733 carboxylic acid esters Chemical group 0.000 description 58
239000000203 mixture Substances 0.000 description 50
230000015572 biosynthetic process Effects 0.000 description 47
239000011734 sodium Substances 0.000 description 47
238000003786 synthesis reaction Methods 0.000 description 45
210000003491 skin Anatomy 0.000 description 41
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 40
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
210000004027 cell Anatomy 0.000 description 38
239000012044 organic layer Substances 0.000 description 38
150000001732 carboxylic acid derivatives Chemical class 0.000 description 37
206010057190 Respiratory tract infections Diseases 0.000 description 36
102100030416 Stromelysin-1 Human genes 0.000 description 33
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 32
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 32
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 32
101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 31
102100036621 Glucosylceramide transporter ABCA12 Human genes 0.000 description 29
101000929652 Homo sapiens Glucosylceramide transporter ABCA12 Proteins 0.000 description 29
210000002510 keratinocyte Anatomy 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
102000006587 Glutathione peroxidase Human genes 0.000 description 26
108700016172 Glutathione peroxidases Proteins 0.000 description 26
102000004890 Interleukin-8 Human genes 0.000 description 26
108090001007 Interleukin-8 Proteins 0.000 description 26
238000004440 column chromatography Methods 0.000 description 26
102000013918 Apolipoproteins E Human genes 0.000 description 25
108010025628 Apolipoproteins E Proteins 0.000 description 25
102100040247 Tumor necrosis factor Human genes 0.000 description 25
101150092476 ABCA1 gene Proteins 0.000 description 24
108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 24
102100036618 ATP-binding cassette sub-family A member 13 Human genes 0.000 description 24
102100033618 ATP-binding cassette sub-family A member 2 Human genes 0.000 description 24
102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 24
101000929660 Homo sapiens ATP-binding cassette sub-family A member 13 Proteins 0.000 description 24
101000801645 Homo sapiens ATP-binding cassette sub-family A member 2 Proteins 0.000 description 24
108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 24
102100024005 Acid ceramidase Human genes 0.000 description 23
102100035401 Ceramide synthase 2 Human genes 0.000 description 23
101001071611 Dictyostelium discoideum Glutathione reductase Proteins 0.000 description 23
101000975753 Homo sapiens Acid ceramidase Proteins 0.000 description 23
101000737604 Homo sapiens Ceramide synthase 2 Proteins 0.000 description 23
101001071608 Homo sapiens Glutathione reductase, mitochondrial Proteins 0.000 description 23
101000823955 Homo sapiens Serine palmitoyltransferase 1 Proteins 0.000 description 23
102100022068 Serine palmitoyltransferase 1 Human genes 0.000 description 23
150000002632 lipids Chemical class 0.000 description 23
101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 description 22
101000844686 Homo sapiens Thioredoxin reductase 1, cytoplasmic Proteins 0.000 description 22
102100026263 Sphingomyelin phosphodiesterase Human genes 0.000 description 22
102100031208 Thioredoxin reductase 1, cytoplasmic Human genes 0.000 description 22
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
229910052786 argon Inorganic materials 0.000 description 20
125000004356 hydroxy functional group Chemical group O* 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
CJQHLMWYSGYVIE-UHFFFAOYSA-N CC(C)Cn1nc(cc1-c1ccc(cc1)-c1ccc(CO)c(c1)S(C)(=O)=O)C(O)=O Chemical compound CC(C)Cn1nc(cc1-c1ccc(cc1)-c1ccc(CO)c(c1)S(C)(=O)=O)C(O)=O CJQHLMWYSGYVIE-UHFFFAOYSA-N 0.000 description 19
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 19
230000004888 barrier function Effects 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
238000005481 NMR spectroscopy Methods 0.000 description 18
238000004128 high performance liquid chromatography Methods 0.000 description 18
239000000556 agonist Substances 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 16
108090000790 Enzymes Proteins 0.000 description 16
101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 16
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 16
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
125000004429 atom Chemical group 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 14
150000001242 acetic acid derivatives Chemical class 0.000 description 13
239000012190 activator Substances 0.000 description 13
230000006698 induction Effects 0.000 description 13
125000006239 protecting group Chemical group 0.000 description 13
239000012453 solvate Substances 0.000 description 13
238000003556 assay Methods 0.000 description 12
229940106189 ceramide Drugs 0.000 description 12
229920001436 collagen Polymers 0.000 description 12
239000003814 drug Substances 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
239000002904 solvent Substances 0.000 description 12
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 11
102000008186 Collagen Human genes 0.000 description 11
108010035532 Collagen Proteins 0.000 description 11
239000003153 chemical reaction reagent Substances 0.000 description 11
RPLOSEMBQMPVEL-UHFFFAOYSA-N dec-1-yn-1-ol Chemical compound CCCCCCCCC#CO RPLOSEMBQMPVEL-UHFFFAOYSA-N 0.000 description 11
210000002950 fibroblast Anatomy 0.000 description 11
239000003446 ligand Substances 0.000 description 11
239000000651 prodrug Substances 0.000 description 11
229940002612 prodrug Drugs 0.000 description 11
238000011200 topical administration Methods 0.000 description 11
230000000699 topical effect Effects 0.000 description 11
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 10
230000032683 aging Effects 0.000 description 10
230000037365 barrier function of the epidermis Effects 0.000 description 10
230000007423 decrease Effects 0.000 description 10
230000004069 differentiation Effects 0.000 description 10
230000002500 effect on skin Effects 0.000 description 10
239000011159 matrix material Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
108700012920 TNF Proteins 0.000 description 9
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
230000004913 activation Effects 0.000 description 9
125000003342 alkenyl group Chemical group 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
125000000753 cycloalkyl group Chemical group 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000002253 acid Substances 0.000 description 8
125000000304 alkynyl group Chemical group 0.000 description 8
230000008859 change Effects 0.000 description 8
210000004207 dermis Anatomy 0.000 description 8
229940079593 drug Drugs 0.000 description 8
210000002615 epidermis Anatomy 0.000 description 8
238000009472 formulation Methods 0.000 description 8
125000000524 functional group Chemical group 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
238000000746 purification Methods 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
210000000434 stratum corneum Anatomy 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
STOKFWJFYUDUKZ-UHFFFAOYSA-N [O-][N+](=O)c1ccc(cc1)-n1cc(nc1CBr)C(F)(F)F Chemical compound [O-][N+](=O)c1ccc(cc1)-n1cc(nc1CBr)C(F)(F)F STOKFWJFYUDUKZ-UHFFFAOYSA-N 0.000 description 7
150000001783 ceramides Chemical class 0.000 description 7
238000013461 design Methods 0.000 description 7
239000002674 ointment Substances 0.000 description 7
239000000523 sample Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000012384 transportation and delivery Methods 0.000 description 7
DORVTLQYGOJSIZ-UHFFFAOYSA-N 1-methylsulfonyl-3-phenylbenzene Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 DORVTLQYGOJSIZ-UHFFFAOYSA-N 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
206010012438 Dermatitis atopic Diseases 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
201000008937 atopic dermatitis Diseases 0.000 description 6
239000000872 buffer Substances 0.000 description 6
125000002843 carboxylic acid group Chemical group 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000006071 cream Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
239000000843 powder Substances 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
210000004927 skin cell Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
RMVCJQKXDRJRGM-UHFFFAOYSA-N CS(=O)(=O)c1cc(ccc1CO)-c1ccc(cc1)-n1cc(nc1CC(O)=O)C(F)(F)F Chemical compound CS(=O)(=O)c1cc(ccc1CO)-c1ccc(cc1)-n1cc(nc1CC(O)=O)C(F)(F)F RMVCJQKXDRJRGM-UHFFFAOYSA-N 0.000 description 5
102000005741 Metalloproteases Human genes 0.000 description 5
108010006035 Metalloproteases Proteins 0.000 description 5
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
206010051246 Photodermatosis Diseases 0.000 description 5
230000005856 abnormality Effects 0.000 description 5
239000013543 active substance Substances 0.000 description 5
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
125000001188 haloalkyl group Chemical group 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 5
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000002243 precursor Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
108090000064 retinoic acid receptors Proteins 0.000 description 5
102000003702 retinoic acid receptors Human genes 0.000 description 5
150000003408 sphingolipids Chemical class 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
AHEKVZVJZSDBLW-UHFFFAOYSA-N CCOC(=O)c1cc(-c2ccc(cc2)-c2cccc(c2)S(C)(=O)=O)n(CC(C)C)n1 Chemical compound CCOC(=O)c1cc(-c2ccc(cc2)-c2cccc(c2)S(C)(=O)=O)n(CC(C)C)n1 AHEKVZVJZSDBLW-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
102000004237 Decorin Human genes 0.000 description 4
108090000738 Decorin Proteins 0.000 description 4
206010012442 Dermatitis contact Diseases 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
125000003545 alkoxy group Chemical group 0.000 description 4
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
210000005175 epidermal keratinocyte Anatomy 0.000 description 4
IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
125000004404 heteroalkyl group Chemical group 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
238000000386 microscopy Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
241000894007 species Species 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700157 Rattus norvegicus Species 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
CPRCFJMTRXIZRE-UHFFFAOYSA-N [O-][N+](=O)c1ccc(cc1)-n1cc(nc1CC#N)C(F)(F)F Chemical compound [O-][N+](=O)c1ccc(cc1)-n1cc(nc1CC#N)C(F)(F)F CPRCFJMTRXIZRE-UHFFFAOYSA-N 0.000 description 3
208000002029 allergic contact dermatitis Diseases 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
229910052805 deuterium Inorganic materials 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000012039 electrophile Substances 0.000 description 3
238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
230000004136 fatty acid synthesis Effects 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
125000003709 fluoroalkyl group Chemical group 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
208000001875 irritant dermatitis Diseases 0.000 description 3
239000003550 marker Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
238000006241 metabolic reaction Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
238000010606 normalization Methods 0.000 description 3
239000012038 nucleophile Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Chemical group 0.000 description 3
230000035699 permeability Effects 0.000 description 3
230000008845 photoaging Effects 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001012 protector Effects 0.000 description 3
238000003753 real-time PCR Methods 0.000 description 3
239000011347 resin Chemical group 0.000 description 3
229920005989 resin Chemical group 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
229910052717 sulfur Chemical group 0.000 description 3
239000011593 sulfur Chemical group 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 2
ABGRSZFACGLQOW-UHFFFAOYSA-N 1-(4-nitrophenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C=C(C(F)(F)F)N=C1 ABGRSZFACGLQOW-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102100023995 Beta-nerve growth factor Human genes 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102100035882 Catalase Human genes 0.000 description 2
102100024308 Ceramide synthase Human genes 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
206010053177 Epidermolysis Diseases 0.000 description 2
241001125671 Eretmochelys imbricata Species 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000014429 Insulin-like growth factor Human genes 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
208000002260 Keloid Diseases 0.000 description 2
206010023330 Keloid scar Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102100031784 Loricrin Human genes 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
206010052437 Nasal discomfort Diseases 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000007399 Nuclear hormone receptor Human genes 0.000 description 2
108020005497 Nuclear hormone receptor Proteins 0.000 description 2
229910003849 O-Si Inorganic materials 0.000 description 2
229910003872 O—Si Inorganic materials 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
208000012641 Pigmentation disease Diseases 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
102000015785 Serine C-Palmitoyltransferase Human genes 0.000 description 2
108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101710108790 Stromelysin-1 Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
206010047642 Vitiligo Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012790 adhesive layer Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
239000007933 dermal patch Substances 0.000 description 2
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
108010061814 dihydroceramide desaturase Proteins 0.000 description 2
OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
210000001117 keloid Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
108010079309 loricrin Proteins 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000001126 phototherapy Methods 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
208000008742 seborrheic dermatitis Diseases 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
230000008591 skin barrier function Effects 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
230000036620 skin dryness Effects 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
238000002076 thermal analysis method Methods 0.000 description 2
238000002411 thermogravimetry Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
108010058734 transglutaminase 1 Proteins 0.000 description 2
230000032258 transport Effects 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000037303 wrinkles Effects 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
CFDCUZAQUHWVIH-UHFFFAOYSA-N (2-methylsulfonyl-4-phenylphenyl)methanol Chemical compound C1=C(CO)C(S(=O)(=O)C)=CC(C=2C=CC=CC=2)=C1 CFDCUZAQUHWVIH-UHFFFAOYSA-N 0.000 description 1
YECBCSZTZYCUKU-UHFFFAOYSA-N (4-bromo-2-methylsulfanylphenyl)methanol Chemical compound CSC1=CC(Br)=CC=C1CO YECBCSZTZYCUKU-UHFFFAOYSA-N 0.000 description 1
WMMVLULSTWDXKF-UHFFFAOYSA-N (4-bromo-2-methylsulfonylphenyl)methanol Chemical compound CS(=O)(=O)C1=CC(Br)=CC=C1CO WMMVLULSTWDXKF-UHFFFAOYSA-N 0.000 description 1
CCEFMUBVSUDRLG-KXUCPTDWSA-N (4R)-limonene 1,2-epoxide Natural products C1[C@H](C(=C)C)CC[C@@]2(C)O[C@H]21 CCEFMUBVSUDRLG-KXUCPTDWSA-N 0.000 description 1
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
LMVCQONNFMKDRF-UHFFFAOYSA-N 1-(2-hydroxyethyl)piperidin-2-one Chemical compound OCCN1CCCCC1=O LMVCQONNFMKDRF-UHFFFAOYSA-N 0.000 description 1
OJNMBVZDZDXYGP-UHFFFAOYSA-N 1-(2-methylpropyl)pyrazole-3-carboxylic acid Chemical compound CC(C)CN1C=CC(C(O)=O)=N1 OJNMBVZDZDXYGP-UHFFFAOYSA-N 0.000 description 1
NVXLKFFSKSEFRK-UHFFFAOYSA-N 1-(4-bromophenyl)-4-(trifluoromethyl)imidazole Chemical compound BrC1=CC=C(C=C1)N1C=NC(=C1)C(F)(F)F NVXLKFFSKSEFRK-UHFFFAOYSA-N 0.000 description 1
WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
OGFKTAMJLKHRAZ-UHFFFAOYSA-N 2,2-dimethoxyacetaldehyde Chemical compound COC(OC)C=O OGFKTAMJLKHRAZ-UHFFFAOYSA-N 0.000 description 1
DNBRZVZQNZKLJP-UHFFFAOYSA-N 2-(2-methylpropyl)-1h-imidazole-5-carboxylic acid Chemical compound CC(C)CC1=NC=C(C(O)=O)N1 DNBRZVZQNZKLJP-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
WOCJTBQTGNIJJZ-UHFFFAOYSA-N 2-(dimethoxymethyl)-5-(trifluoromethyl)-1h-imidazole Chemical compound COC(OC)C1=NC(C(F)(F)F)=CN1 WOCJTBQTGNIJJZ-UHFFFAOYSA-N 0.000 description 1
DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
DGOQIJKUNBFISY-UHFFFAOYSA-N 2-methylpropylhydrazine;hydrochloride Chemical compound Cl.CC(C)CNN DGOQIJKUNBFISY-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
VLVSKRNYKADZMG-UHFFFAOYSA-N 3-(4-bromophenyl)-5-propan-2-yl-1h-pyrazole Chemical compound N1C(C(C)C)=CC(C=2C=CC(Br)=CC=2)=N1 VLVSKRNYKADZMG-UHFFFAOYSA-N 0.000 description 1
SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
DGQZJPIQHLSYJA-UHFFFAOYSA-N 4-[4-(trifluoromethyl)imidazol-1-yl]aniline Chemical compound C1=CC(N)=CC=C1N1C=C(C(F)(F)F)N=C1 DGQZJPIQHLSYJA-UHFFFAOYSA-N 0.000 description 1
RRNVSDPZVLBTGE-UHFFFAOYSA-N 4-bromo-2-methylsulfanylbenzoic acid Chemical compound CSC1=CC(Br)=CC=C1C(O)=O RRNVSDPZVLBTGE-UHFFFAOYSA-N 0.000 description 1
WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
NIEUMLZXCZNYEF-UHFFFAOYSA-N 5-(4-bromophenyl)-1,2-dihydropyrazol-3-one Chemical compound C1=CC(Br)=CC=C1C1=CC(=O)NN1 NIEUMLZXCZNYEF-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
102000041092 ABC transporter family Human genes 0.000 description 1
108091060858 ABC transporter family Proteins 0.000 description 1
101150005647 ABCG1 gene Proteins 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Natural products O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
102000006772 Acid Ceramidase Human genes 0.000 description 1
108020005296 Acid Ceramidase Proteins 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
101150094024 Apod gene Proteins 0.000 description 1
102100022954 Apolipoprotein D Human genes 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
241001480043 Arthrodermataceae Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
JFUAOAGQQWCAAH-UHFFFAOYSA-N BrC1=CC=C(C=C1)N1C(=NC(=C1)C(=O)OCC)CC(C)C Chemical compound BrC1=CC=C(C=C1)N1C(=NC(=C1)C(=O)OCC)CC(C)C JFUAOAGQQWCAAH-UHFFFAOYSA-N 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
0 C*[n]1nc(*)c(*)c1-c1ccc(*)cc1 Chemical compound C*[n]1nc(*)c(*)c1-c1ccc(*)cc1 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
RWFPSRITUCFTNH-UHFFFAOYSA-N CC(C)CC(=N)Nc1ccc(Br)cc1 Chemical compound CC(C)CC(=N)Nc1ccc(Br)cc1 RWFPSRITUCFTNH-UHFFFAOYSA-N 0.000 description 1
MWTOSPQLGNIEQC-UHFFFAOYSA-N CC(C)c1cc(-c2ccc(cc2)-c2cccc(c2)S(C)(=O)=O)n(CC(O)=O)n1 Chemical compound CC(C)c1cc(-c2ccc(cc2)-c2cccc(c2)S(C)(=O)=O)n(CC(O)=O)n1 MWTOSPQLGNIEQC-UHFFFAOYSA-N 0.000 description 1
DCYYFWPFSDMRRX-UHFFFAOYSA-N CCC(N=C1CC(C)C)=CN1C(C=C1)=CC=C1C1=CC(S(C)(=O)=O)=CC=C1 Chemical compound CCC(N=C1CC(C)C)=CN1C(C=C1)=CC=C1C1=CC(S(C)(=O)=O)=CC=C1 DCYYFWPFSDMRRX-UHFFFAOYSA-N 0.000 description 1
YIDLXYAXOQMNNS-UHFFFAOYSA-N CCOC(=O)c1cc(-c2ccc(Br)cc2)n(CC(C)C)n1 Chemical compound CCOC(=O)c1cc(-c2ccc(Br)cc2)n(CC(C)C)n1 YIDLXYAXOQMNNS-UHFFFAOYSA-N 0.000 description 1
BHPUWTLAPLMVQB-UHFFFAOYSA-N COC(OC)c1nc(cn1-c1ccc(cc1)[N+]([O-])=O)C(F)(F)F Chemical compound COC(OC)c1nc(cn1-c1ccc(cc1)[N+]([O-])=O)C(F)(F)F BHPUWTLAPLMVQB-UHFFFAOYSA-N 0.000 description 1
101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
108030002440 Catalase peroxidases Proteins 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102100035418 Ceramide synthase 4 Human genes 0.000 description 1
208000009043 Chemical Burns Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
241001454694 Clupeiformes Species 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
206010056340 Diabetic ulcer Diseases 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
108010039731 Fatty Acid Synthases Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
101000737544 Homo sapiens Ceramide synthase 4 Proteins 0.000 description 1
101001039207 Homo sapiens Low-density lipoprotein receptor-related protein 8 Proteins 0.000 description 1
101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 1
101000603962 Homo sapiens Oxysterols receptor LXR-alpha Proteins 0.000 description 1
101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 1
101000979912 Homo sapiens Sphingomyelin phosphodiesterase 2 Proteins 0.000 description 1
101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 1
101000629597 Homo sapiens Sterol regulatory element-binding protein 1 Proteins 0.000 description 1
101000629605 Homo sapiens Sterol regulatory element-binding protein 2 Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000003815 Interleukin-11 Human genes 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000003812 Interleukin-15 Human genes 0.000 description 1
108090000172 Interleukin-15 Proteins 0.000 description 1
102000004125 Interleukin-1alpha Human genes 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000000704 Interleukin-7 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
CCEFMUBVSUDRLG-XNWIYYODSA-N Limonene-1,2-epoxide Chemical compound C1[C@H](C(=C)C)CCC2(C)OC21 CCEFMUBVSUDRLG-XNWIYYODSA-N 0.000 description 1
206010024570 Lip swelling Diseases 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102100040705 Low-density lipoprotein receptor-related protein 8 Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
102100030157 Microphthalmia-associated transcription factor Human genes 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
240000001307 Myosotis scorpioides Species 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102100030350 Prolactin-inducible protein Human genes 0.000 description 1
102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
238000001530 Raman microscopy Methods 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000882890 Renova Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 description 1
102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
206010070995 Vascular compression Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JPKOLMLTXKBHQB-UHFFFAOYSA-N Volucrin Natural products COc1cc(OC)c2c(ccc3c(c(O)c(O)cc23)c4c(O)c(O)cc5c4ccc6cc(OC)cc(OC)c56)c1 JPKOLMLTXKBHQB-UHFFFAOYSA-N 0.000 description 1
OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
QZDZTHLANDGZGY-UHFFFAOYSA-N [2-methylsulfonyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CO)C(S(C)(=O)=O)=C1 QZDZTHLANDGZGY-UHFFFAOYSA-N 0.000 description 1
BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Chemical group CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical group 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000004419 alkynylene group Chemical group 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
235000019513 anchovy Nutrition 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000005362 aryl sulfone group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000000732 arylene group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
229940054720 avage Drugs 0.000 description 1
229940058140 avita Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000010094 cellular senescence Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
102000049842 cholesterol binding protein Human genes 0.000 description 1
108010011793 cholesterol binding protein Proteins 0.000 description 1
229960002842 clobetasol Drugs 0.000 description 1
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
238000013329 compounding Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
201000010251 cutis laxa Diseases 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000037304 dermatophytes Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
238000002389 environmental scanning electron microscopy Methods 0.000 description 1
230000036566 epidermal hyperplasia Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
GETVBTMFGVOGRW-UHFFFAOYSA-N ethyl 2-hydrazinylacetate Chemical compound CCOC(=O)CNN GETVBTMFGVOGRW-UHFFFAOYSA-N 0.000 description 1
HZZRIIPYFPIKHR-UHFFFAOYSA-N ethyl 2-hydrazinylacetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNN HZZRIIPYFPIKHR-UHFFFAOYSA-N 0.000 description 1
PBDYXCKRDRCJDC-UHFFFAOYSA-N ethyl 3-(4-bromophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=C(Br)C=C1 PBDYXCKRDRCJDC-UHFFFAOYSA-N 0.000 description 1
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
YAXZGVSOAFLCQS-UHFFFAOYSA-N ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(Br)C=C1 YAXZGVSOAFLCQS-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000004428 fluoroalkoxy group Chemical group 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002305 glucosylceramides Chemical class 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036074 healthy skin Effects 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000037315 hyperhidrosis Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000010985 leather Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
102000019758 lipid binding proteins Human genes 0.000 description 1
108091016323 lipid binding proteins Proteins 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000007403 mPCR Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
230000003061 melanogenesis Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
231100000435 percutaneous penetration Toxicity 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
230000009120 phenotypic response Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
208000002440 photoallergic dermatitis Diseases 0.000 description 1
208000007578 phototoxic dermatitis Diseases 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
208000006934 radiodermatitis Diseases 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
229940059527 renova Drugs 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
229940002683 retin-a Drugs 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
239000011607 retinol Substances 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000009758 senescence Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
DRNXZGJGRSUXHW-UHFFFAOYSA-N silyl carbamate Chemical class NC(=O)O[SiH3] DRNXZGJGRSUXHW-UHFFFAOYSA-N 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
230000005808 skin problem Effects 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000012306 spectroscopic technique Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000036575 thermal burns Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
108010074309 thioredoxin glutathione reductase Proteins 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1